A RANDOMIZED MULTICENTRIC STUDY COMPARING ALTERNATING COMBINATION CHEMOTHERAPY (VCMP VBAP) AND MELPHALAN-PREDNISONE IN MULTIPLE-MYELOMA

被引：13

作者：

BLADE, J ^{[1
]}

MIGUEL, JS ^{[1
]}

ALCALA, A ^{[1
]}

MALDONADO, J ^{[1
]}

GARCIACONDE, J ^{[1
]}

MORO, MJ ^{[1
]}

SANZ, MAS ^{[1
]}

ALONSO, C ^{[1
]}

ZUBIZARRETA, A ^{[1
]}

BESSES, C ^{[1
]}

MARTIN, JMH ^{[1
]}

BESALDUCH, J ^{[1
]}

NIETO, LH ^{[1
]}

CALVO, JF ^{[1
]}

RUBIO, D ^{[1
]}

MAYANS, JR ^{[1
]}

SANCHIS, J ^{[1
]}

GALINDO, RJ ^{[1
]}

TORTOSA, J ^{[1
]}

ORTEGA, F ^{[1
]}

DOMINGO, A ^{[1
]}

FAURA, MV ^{[1
]}

DANIELS, M ^{[1
]}

ROZMAN, C ^{[1
]}

ESTAPE, J ^{[1
]}

机构：

[1] HOSP CLIN BARCELONA, SPANISH SOC HAEMATOL, BARCELONA 36, SPAIN

来源：

BLUT | 1990年 / 60卷 / 06期

关键词：

Combination chemotherapy; MP treatment; Multiple myeloma; Survival; VCMP/VBAP;

D O I：

10.1007/BF01737844

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Between January 1985 and December 1988, 386 patients with multiple myeloma were randomized to receive either MP or combination chemotherapy based on alternating cycles of VCMP and VBAP. The major prognostic parameters did not differ significantly between both treatment groups. A significantly higher proportion of objective responses was observed with combination chemotherapy as compared to MP (47.8 vs 32.2, P = 0.01). The median survival for all patients was 33.5 months. So far no significant differences were found when comparing the survival curves from both groups of patients. However, the median survival of MP-treated patients is 26.8 months, whereas the median survival of patients receiving VCMP/VBAP has not yet been reached. The definitive analysis must await the evaluation of all patients entered into the study and a longer follow-up time. © 1990 Springer-Verlag.

引用

页码：319 / 322

页数：4

共 25 条

[1]

ABRAMSON N, 1982, CANCER TREAT REP, V66, P1273

[2] TREATMENT FOR MULTIPLE MYELOMA - COMBINATION CHEMOTHERAPY WITH DIFFERENT MELPHALAN DOSE REGIMENS [J].

ALEXANIAN, R ;

HAUT, A ;

KHAN, AU ;

LANE, M ;

MCKELVEY, EM ;

MIGLIORE, PJ ;

STUCKEY, WJ ;

WILSON, HE .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 208 (09) :1680-+

[3]

ALEXANIAN R, 1984, CANCER, V53, P583, DOI 10.1002/1097-0142(19840201)53:3<583::AID-CNCR2820530336>3.0.CO

[4]

2-1

[5] PROGRESS IN THE TREATMENT OF PLASMA-CELL MYELOMA [J].

BERGSAGEL, D .

JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (08) :510-512

[6] CHEMOTHERAPY OF PLASMA-CELL MYELOMA AND THE INCIDENCE OF ACUTE-LEUKEMIA [J].

BERGSAGEL, DE ;

BAILEY, AJ ;

LANGLEY, GR ;

MACDONALD, RN ;

WHITE, DF ;

MILLER, AB .

NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (14) :743-748

[7] CHEMOTHERAPY OF MYELOMA - DRUG-COMBINATIONS VERSUS SINGLE AGENTS, AN OVERVIEW, AND COMMENTS ON ACUTE-LEUKEMIA IN MYELOMA [J].

BERGSAGEL, DE .

HEMATOLOGICAL ONCOLOGY, 1988, 6 (02) :159-166

[8] PLASMACYTIC MYELOMA - A STUDY OF RELATIONSHIP OF SURVIVAL TO VARIOUS CLINICAL MANIFESTATIONS AND ANOMALOUS PROTEIN TYPE IN 112 PATIENTS [J].

CARBONE, PP ;

KELLERHOUSE, LE ;

GEHAN, EA .

AMERICAN JOURNAL OF MEDICINE, 1967, 42 (06) :937-+

[9] SINGLE, SEQUENTIAL, AND MULTIPLE ALKYLATING AGENT THERAPY FOR MULTIPLE-MYELOMA - A CALGB STUDY [J].

COOPER, MR ;

MCINTYRE, OR ;

PROPERT, KJ ;

KOCHWA, S ;

ANDERSON, K ;

COLEMAN, M ;

KYLE, RA ;

PRAGER, D ;

RAFLA, S ;

ZIMMER, B .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1331-1339

[10] IMPROVED SURVIVAL DURATION WITH COMBINATION CHEMOTHERAPY INDUCTION FOR MULTIPLE-MYELOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY [J].

DURIE, BGM ;

DIXON, DO ;

CARTER, S ;

STEPHENS, R ;

RIVKIN, S ;

BONNET, J ;

SALMON, SE ;

DABICH, L ;

FILES, JC ;

COSTANZI, JJ .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (08) :1227-1237

← 1 2 3 →